N-Formyl-Nle-Leu-Phe-Nle-Tyr-Lys TFA

N-Formyl-Nle-Leu-Phe-Nle-Tyr-Lys TFA is a synthetic hexapeptide featuring a formylated N-terminus and a sequence incorporating norleucine, leucine, phenylalanine, tyrosine, and lysine residues. As a structurally modified analog of classic chemotactic peptides, it is designed to mimic and probe the functional domains of biologically active peptides involved in cell signaling and receptor activation. Its unique sequence and chemical modifications make it a valuable tool for dissecting the molecular mechanisms underlying peptide-receptor interactions, with particular relevance to studies of immune cell chemotaxis, G protein-coupled receptor (GPCR) function, and structure-activity relationships in peptide biology.

Chemotaxis research: The hexapeptide is widely utilized in the investigation of leukocyte chemotaxis, serving as a model ligand for formyl peptide receptors (FPRs) on immune cells such as neutrophils and monocytes. By providing a defined and controllable stimulus, it enables researchers to elucidate the signaling pathways governing cell migration, directional sensing, and actin cytoskeleton remodeling. The inclusion of norleucine residues enhances metabolic stability, allowing for more precise kinetic and mechanistic analysis in vitro.

Receptor binding assays: The compound is instrumental in binding studies aimed at characterizing ligand affinity, selectivity, and receptor activation profiles for FPR subtypes. Its well-defined structure supports the quantitative assessment of peptide-receptor interactions using radioligand binding, fluorescence polarization, or surface plasmon resonance techniques. These applications yield critical insights into the pharmacological properties of receptor-ligand pairs and inform the rational design of novel modulators or antagonists.

Peptide structure-activity relationship (SAR) studies: Researchers employ this hexapeptide in systematic SAR investigations to delineate the contribution of individual amino acid residues and chemical modifications to biological activity. The presence of norleucine and formylation at the N-terminus provides a platform for comparative studies with native and analog peptides, facilitating the identification of key determinants for receptor recognition and signal transduction. Such work advances the broader understanding of peptide engineering principles.

Intracellular signaling pathway analysis: The peptide is used to stimulate immune cells in vitro, permitting the dissection of downstream intracellular signaling cascades triggered by FPR engagement. By monitoring second messenger generation, kinase activation, and gene expression changes, scientists can map the molecular events linking extracellular peptide recognition to functional cellular responses. These studies are foundational for unraveling the complexity of GPCR-mediated signaling networks.

Peptide-based assay development: Owing to its synthetic accessibility and well-characterized activity profile, the hexapeptide serves as a standard or reference ligand in the development and optimization of bioassays targeting chemotactic pathways. Its application in high-throughput screening, reporter gene assays, or cell migration platforms supports the discovery and validation of new modulators of immune cell function. The reliability and reproducibility afforded by this peptide make it a preferred choice for assay calibration and methodological benchmarking in peptide research.

1. Myotropic activity and immunolocalization of selected neuropeptides of the burying beetle Nicrophorus vespilloides (Coleoptera: Silphidae)

2. Proinsulin C-peptide and insulin: Limited pattern similarities of interest in inter-peptide interactions but no C-peptide effect on insulin and IGF-1 receptor signaling

3. Oleic acid and glucose regulate glucagon-like peptide 1 receptor expression in a rat pancreatic ductal cell line

4. cRGD-functionalized, DOX-conjugated, and 64Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging

5. Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis